ReportGem ReportGem EN

普通外文研报

Dental KOL Call: Healthy Implant Growth; Solid Aligner Growth; +ALGN Share

发布日期: 2026-06-09研究机构: Jefferies报告页数: 9原文语言: 英语证据页码: 1

研报英文原文证据摘录

Dental KOL Call: Healthy Implant Growth; Solid Aligner Growth; +ALGN Share

Expert

Series

USA | Medical Supplies & Devices EquityJuneResearch9, 2026

Dental KOL Call: Healthy Implant Growth; Solid

Aligner Growth; +ALGN Share

Key Takes from our KOL call with Dr. Marcos Magar, dentist: 1/ Implant demand

accelerating as better-informed patients favouring LT solutions. 2/ Pricing

still key constraint vs bridges. 3/ Clear aligners growing (~20% yoy). 4/ Mix

.

volatile, driven by geo + strong Invisalign brand pull. 5/ Limited cost delta (~

$300) supports pricing dispersion. 6/ Digital fully embedded. 7/ Tech adoption

selective, constrained by ROI & workflow stickiness.

Implants accelerating as patients shift to long-term solutions. Patient behaviour has shifted over

~24m, driven by stronger education (web, peers). Decision-making is now more LT-focused, with

patients increasingly favouring implants vs restorations. Rising scepticism on crowns/root canals

(durability, cumulative cost) is pushing more patients toward full rehab decisions. Demand remains

geo-divergent, with affordability still a constraint. Implants remain a premium option vs bridges.

Implants are becoming the Standard of Care. This is driven by rising patient awareness of their LT

value vs restorative work. The KOL is seeing rapid volume growth in his practices (~150 implants

in '26, potentially doubling YoY). While Dr. Magar narrows the pricing gap vs bridges, pricing

remains a barrier to adoption (~$4k vs ~$3.6–3.8k bridge) alongside patient suitability, despite

more conservative clinical benefits.

Dr. Magar sees STMN & Nobel as preferred implant manufacturers. Our KOL relies on Nobel

(~75%) and STMN (~25% / mainly BLT), with the latter more expensive ($200-250/implant vs ~

$100–150).

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。

打开研报阅读器